Johnson & Johnson today announced it will showcase advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society Annual Meeting. The firm will showcase new developments in pulsed field ablation and innovations within cardiac mapping and imaging technologies.
Johnson & Johnson will introduce the CARTOSOUND SONATA Module with AI technology, together with the CARTO System, at HRS 2026. This technology is designed to automatically transform intracardiac echo pictures into cardiac maps. It allows medical professionals to make accurate models of different chambers of the heart. Moreover, this tool assists medical professionals in detecting and labeling cardiac structures.
CARTOSOUND SONATA is integrated with two devices, namely, SOUNDSTAR CRYSTAL 2D ICE and NUVISION NAV 4D ICE ultrasound catheters. The use of these tools allows doctors to make treatment plans related to various heart rhythm disorders. These include atrial fibrillation, ventricular tachycardia, and complex concomitant cardiac procedures.
“In my experience, CARTOSOUND SONATA elevates imaging capabilities by streamlining the process of building detailed maps of the heart across multiple chambersi using both 2D and 4D ICE technologiesiv,v, even during the most complex concomitant procedures,ii,iii” said Luigi Di Biase2, MD, PhD, FACC, FHRS, System Director Electrophysiology at Montefiore Health System, Professor of Medicine (Cardiology) Albert Einstein College of Medicine at Montefiore Hospital. “This new module continues to demonstrate the power and versatility of the CARTO System and is a clear example of its continued evolution as a key platform in electrophysiology.”
CARTO System Legacy and VARIPULSE Platform Updates
The year 2026 also marks the 30th anniversary of the CARTO System in electrophysiology innovation. Johnson & Johnson will celebrate decades of advancements that shaped modern approaches to arrhythmia care. The CARTO System evolved from early electroanatomical mapping into an advanced AI-powered clinical platform. It continues to serve as a central system connecting technologies across the electrophysiology portfolio.
“For 30 years, the CARTO System has led progress in electrophysiology, serving as the foundation of a connected platform that brings together imaging, mapping, and therapy. Looking into the future, we are decisively moving forward with continuous advancements toward new frontiers in cardiac mapping,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “As we introduce CARTOSOUND SONATA and continue to progress our PFA technologies, we remain committed to innovation that improves how arrhythmias are understood and treated, while evolving and pushing what’s possible in AFib care.”
At HRS 2026, Johnson & Johnson will present new clinical and real-world data on the VARIPULSE Platform. The data highlights safety improvements, workflow efficiency, and strong real-world patient outcomes in atrial fibrillation treatment. The VARIPULSE Platform integrates fully with the CARTO System for consistent and reproducible treatment performance. In the United States, VARIPULSE Plus introduces automated irrigation flow control to enhance safety and procedural consistency. Additionally, the company launched VARIPULSE Pro3 in Europe with a new pulse sequence for improved workflow efficiency.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
